Preclinical News and Research

RSS

Exploring the anticancer potential of medicinal plants

Cancer remains one of the leading global causes of mortality, with an estimated increase in cases due to lifestyle, environmental, and genetic factors.

8 Nov 2024

MD Anderson launches new institute for advancing cell therapy

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.

8 Nov 2024

Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial cell cycle progression.

8 Nov 2024

Adipo Therapeutics shares results of studies on potential obesity treatment

Adipo Therapeutics LLC, a late-stage, preclinical biopharmaceutical company developing a potential treatment for obesity and related metabolic disorders, presented data from two studies at the annual meeting of The Obesity Society in San Antonio.

7 Nov 2024

Understanding gut microbial imbalance in pancreatic cancer development and treatment

Pancreatic ductal adenocarcinoma (PDAC) is recognized as one of the most lethal cancers, with an estimated five-year survival rate of approximately 10%.

7 Nov 2024

Aptamer extends agreement with genetic medicines customer

Aptamer's Optimer technology achieves key milestones in genetic medicine delivery, enhancing targeting specificity and advancing towards preclinical studies.

From Aptamer Group 7 Nov 2024

Study uncovers how certain E. coli bacteria in the gut promote colon cancer

Scientists have uncovered how certain E. coli bacteria in the gut promote colon cancer by binding to intestinal cells and releasing a DNA-damaging toxin.

6 Nov 2024

Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy

A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer EBV-positive cancer therapies.

5 Nov 2024

New active substance shows promise in treating acute sudden hearing loss

A research team led by MedUni Vienna has investigated AC102, a new active substance that offers hope of an effective treatment for acute sudden hearing loss. The latest results have been published in the scientific journal "Cell Death & Disease".

5 Nov 2024

Lupus Research Alliance announces 33 studies to be presented at ACR Convergence 2024

The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research affiliate Lupus Therapeutics, will be presented at ACR Convergence 2024.

5 Nov 2024

International experts propose revised Alzheimer's disease definitions

Today, Prof. Howard Feldman presented revised diagnostic criteria for Alzheimer's disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid on behalf of the International Working Group (IWG).

1 Nov 2024

New therapeutic target overcomes ovarian cancer immunotherapy resistance

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance.

1 Nov 2024

Drug repurposing offers hope for SYNGAP1 patients

The SynGAP Research Fund 501(c)(3) has awarded a pair of grants to Dr. Clement Chow, a geneticist and Associate Professor in the Department of Human Genetics at the University of Utah. These grants are crucial steps in advancing therapeutic development for SYNGAP1-Related Disorders (SRD).

30 Oct 2024

Scientists discover novel compound to combat age-related blindness

Rensselaer Polytechnic Institute's Christopher Cioffi, Ph.D., Thomas and Constance D'Ambra Professor in Organic Chemistry, has been collaborating with Konstantin Petrukhin, Ph.D., Professor of Ophthalmic Science at Colombia University, to develop compounds to treat dry age-related macular degeneration (AMD) and Stargardt disease - both blindness-causing diseases.

28 Oct 2024

Researchers uncover key mechanisms of CRISPR gene editing

CRISPR/Cas9 is a gene editing tool that has revolutionized biomedical research and led to the first FDA-approved CRISPR-based gene therapy.

28 Oct 2024

C. elegans model system accelerates discovery of amyloid inhibitors

An international team led by researchers at the University of Toronto has developed an efficient and robust system, using the C. elegans nematode, to screen for compounds that can stop the growth of amyloid proteins.

28 Oct 2024

Novel class of encrypted peptides offers hope against drug-resistant bacteria

In a significant advance against the growing threat of antibiotic-resistant bacteria, researchers have identified a novel class of antimicrobial agents known as encrypted peptides, which may expand the immune system's arsenal of tools to fight infection.

28 Oct 2024

Unlocking the secrets of Usher syndrome

The mistakes are small but carry severe consequences: In Usher syndrome, genetic mutations cause both hearing and vision loss. Cell biologist Professor Uwe Wolfrum from Mainz University is researching the molecular background of this rare genetic disorder - supported by foundations and, not least, by affected individuals themselves

28 Oct 2024

UCLA researchers identify key protein in heart healing after attack

UCLA scientists have identified the protein GPNMB as a critical regulator in the heart's healing process after a heart attack.

25 Oct 2024

RNA modifications and their role in cancer development

Cancer, a disease with global impact, is intricately linked to dysregulated gene expression, which is influenced by both genetic mutations and epigenetic changes, including RNA modifications.

25 Oct 2024